Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review

This publication has 71 references indexed in Scilit:

• The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
  Genetics in Medicine, 2009
• Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients
  The Pharmacogenomics Journal, 2007
• Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals
  Anti-Cancer Drugs, 2007
• Metastatic Colorectal Cancer
  Drugs, 2007
• Management of advanced colorectal cancer: state of the art
  British Journal of Cancer, 2006
• Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A Family Members and its Role in Patient Response to Irinotecan
  Drug Metabolism Reviews, 2006
• Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
  JNCI Journal of the National Cancer Institute, 2004
• Comprehensive UGT1A1 Genotyping in a Japanese Population by Pyrosequencing
  Clinical Chemistry, 2003
• The treatment of advanced colorectal cancer: where are we now and where do we go?
  Best Practice & Research Clinical Gastroenterology, 2002
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
  The Lancet, 1998